Device Trial Radar · NCT06965504
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 2, 2026
Primary completion
Dec 1, 2028
Study completion Jun 1, 2029
Sponsor
- Lead sponsor
- Abiomed Inc.Public (JNJ)
- Sponsor type
- Industry
- Collaborators
- Johnson & Johnson
- First posted
- May 11, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
Conditions
- Heart Failure
- Cardiogenic Shock
- Reduced Ejection Fraction Heart Failure
Interventions
Impella 5.5 SmartAssistDevice
The intervention is Impella 5.5 with SmartAssist® support combined with protocolized guideline directed medical therapy (GDMT) and HF-CS best practices.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite of all-cause death, HF hospitalization, and heart replacement (heart transplantation or durable LVAD implantation)Time frame: Timeframe: 180-days post-enrollment
Locations
23 sites in 1 country. Site status is shown where the registry gives one.
Sutter Medical Center Sacramento
Sacramento, California · Not yet recruiting
California Pacific Medical Center
San Francisco, California · Not yet recruiting
NCH Rooney Heart Institute
Naples, Florida · Not yet recruiting
20 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.